Phenotypes associated with this allele

• Allele Symbol: Tg(tetO-TGFB1*C223S*C225S)1Glk
• Allele Name: transgene insertion 1, Adam Glick
• Allele ID: MGI:3815091
• Summary: 3 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cx1	Tg(Pax8-rtTA2S*M2)1Koes/0 Tg(tetO-TGFB1*C223S*C225S)1Glk/0	involves: C57BL/6 * DBA	MGI:3815408
cx2	Tg(KRT5-tTA)1216Glk/0 Tg(tetO-TGFB1*C223S*C225S)1Glk/0	involves: FVB/N	MGI:3815534
cx3	Tg(KRT5-rtTA)1Glk/0 Tg(tetO-TGFB1*C223S*C225S)1Glk/0	involves: FVB/N	MGI:3815535

Genotype
MGI:3815408

cx1

• Allelic Composition: Tg(Pax8-rtTA2S*M2)1Koes/0; Tg(tetO-TGFB1*C223S*C225S)1Glk/0
• Genetic Background: involves: C57BL/6 * DBA

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

renal/urinary system

renal fibrosis ( J:140925 )

• doxycycline-treated mice (six cycles of discontinuous treatment) show distinct renal fibrosis

Genotype
MGI:3815534

cx2

• Allelic Composition: Tg(KRT5-tTA)1216Glk/0; Tg(tetO-TGFB1*C223S*C225S)1Glk/0
• Genetic Background: involves: FVB/N

mortality/aging

mortality/aging ( J:70670 )

N • when pregnant mice are maintained on 10 ug/ml or higher doxycycline, double-transgenic mice with normal morphology are born at expected ratios

perinatal lethality, complete penetrance ( J:70670 )

• 1-5 ug/ml doxycycline treatment during gestation allows full-term development of double-transgenic mice, but pups are born dead or die shortly after birth

prenatal lethality, complete penetrance ( J:70670 )

• no live animals are obtained in litters born when the pregnant mouse does not receive doxycycline during gestation

growth/size/body

decreased body size ( J:70670 )

• animals born dead or dying shortly after birth with 1-5 ug/ml doxycycline treatment during gestation are runted

immune system

skin inflammation ( J:70670 )

• weanlings treated by doxycycline withdrawal displays a variable neutrophilic infiltrate characterized by microabcesses within and above cornified layers

dermatitis ( J:70670 )

• weanlings treated by doxycycline withdrawal develop dermatitis on scalp and shoulders, as well as ventral surface; dermatitis extends caudally with time

cellular

decreased cell proliferation ( J:70670 )

• cell proliferation in the epidermis is significantly reduced in double transgenic newborns after 1-5 ug/ml doxycycline treatment during gestation

integument

abnormal coat/ hair morphology ( J:70670 )

• abnormalities manifest several weeks later than in Tg(tetO-TGFB1*C223S*C225S)1Glk/Tg(KRT5-rtTA)1Glk double-transgenic mice treated with doxycycline

• with reintroduction of doxycycline at >5 ug/ml in diet, nearly complete hair regrowth is observed within 14 days

progressive hair loss ( J:70670 )

• weanlings treated by doxycycline withdrawal display progressive hair loss

abnormal hair follicle morphology ( J:70670 )

• in weanlings treated by doxycycline withdrawal, many hair follicles appear hyperplastic with abnormal morphologies

decreased hair follicle number ( J:70670 )

• hair follicle density is reduced in affected newborns after 1-5 ug/ml doxycycline treatment during gestation

abnormal skin morphology ( J:70670 )

• hyperkeratosis and other abnormalities manifest several weeks later than in Tg(tetO-TGFB1*C223S*C225S)1Glk/Tg(KRT5-rtTA)1Glk double-transgenic mice treated with doxycycline

• with reintroduction of doxycycline at >5 ug/ml in diet, hyperkeratotic phenotype is reversed

abnormal dermal layer morphology ( J:70670 )

• dermal layer in affected double-transgenic newborns is hypervascular after 1-5 ug/ml doxycycline treatment during gestation

thick dermal layer ( J:70670 )

• significant thickening is observed in weanlings treated by doxycycline withdrawal

abnormal epidermal layer morphology ( J:70670 )

• affected double-transgenic newborns after 1-5 ug/ml doxycycline treatment during gestation have reduced number of cornified layers

hyperkeratosis ( J:70670 )

• weanlings treated by doxycycline withdrawal develop hyperkeratosis

acanthosis ( J:70670 )

• epidermis of affected mice (weanlings treated by doxycycline withdrawal) becomes acanthotic

epidermal hyperplasia ( J:70670 )

• epidermis of affected mice (weanlings treated by doxycycline withdrawal) exhibits hyperplasia

thin epidermis ( J:70670 )

• epidermis is thinner in affected double-transgenic newborns than single-transgenic pups

reddish skin ( J:70670 )

• animals born dead or dying shortly after birth with 1-5 ug/ml doxycycline treatment during gestation have shiny tight erythemic skin

shiny skin ( J:70670 )

tight skin ( J:70670 )

abnormal skin physiology ( J:70670 )

• abnormalities manifest several weeks later than in Tg(tetO-TGFB1*C223S*C225S)1Glk/Tg(KRT5-rtTA)1Glk double-transgenic mice treated with doxycycline

skin inflammation ( J:70670 )

• weanlings treated by doxycycline withdrawal displays a variable neutrophilic infiltrate characterized by microabcesses within and above cornified layers

dermatitis ( J:70670 )

• weanlings treated by doxycycline withdrawal develop dermatitis on scalp and shoulders, as well as ventral surface; dermatitis extends caudally with time

Genotype
MGI:3815535

cx3

• Allelic Composition: Tg(KRT5-rtTA)1Glk/0; Tg(tetO-TGFB1*C223S*C225S)1Glk/0
• Genetic Background: involves: FVB/N

mortality/aging

mortality/aging ( J:70670 )

N • double-transgenic mice with normal morphology are born at expected ratios when no doxycycline treatment is given to the dam

immune system

skin inflammation ( J:70670 )

• epidermis of weaning-aged mice dosed with doxycycline displays a variable neutrophilic infiltrate characterized by microabcesses within and above cornified layers

dermatitis ( J:70670 )

• weaning-aged mice dosed with doxycycline develop dermatitis on scalp and shoulders, as well as ventral surface, within 3-4 weeks; dermatitis extends caudally with time

cellular

increased keratinocyte apoptosis ( J:70670 )

• treatment with doxycycline induces keratinocyte apoptosis

abnormal cell proliferation ( J:70670 )

• cell proliferation in hyperplastic dermis of doxycycline-treated animals is elevated

decreased cell proliferation ( J:70670 )

• when adult mice undergo depilation and receive doxycycline treatment, cell proliferation is significantly reduced compared to mice which receive no doxycycline or single-transgenic controls

integument

increased keratinocyte apoptosis ( J:70670 )

• treatment with doxycycline induces keratinocyte apoptosis

skin inflammation ( J:70670 )

• epidermis of weaning-aged mice dosed with doxycycline displays a variable neutrophilic infiltrate characterized by microabcesses within and above cornified layers

dermatitis ( J:70670 )

• weaning-aged mice dosed with doxycycline develop dermatitis on scalp and shoulders, as well as ventral surface, within 3-4 weeks; dermatitis extends caudally with time

progressive hair loss ( J:70670 )

• weaning-aged mice dosed with doxycycline display progressive hair loss within 3-4 weeks

abnormal hair follicle morphology ( J:70670 )

• in weaning-aged mice dosed with doxycycline, many hair follicles appear hyperplastic with abnormal morphologies

• in animals treated with doxycycline, nearly all hair follicles have proliferating cells in the outer root sheath particularly in the infundibular region

decreased hair follicle number ( J:70670 )

• hair follicle density is significantly reduced in weaning-aged mice dosed with doxycycline

abnormal hair cycle ( J:70670 )

• treatment of animals with doxycycline causes keratinocytes to undergo growth arrest

dermal hyperplasia ( J:70670 )

• increased cellularity is observed in weaning-aged mice dosed with doxycycline

thick dermal layer ( J:70670 )

• significant thickening is observed in weaning-aged mice dosed with doxycycline

hyperkeratosis ( J:70670 )

• weaning-aged mice dosed with doxycycline develop hyperkeratosis within 3-4 weeks

acanthosis ( J:70670 )

• epidermis of affected mice (weanlings treated with doxycycline) becomes acanthotic

epidermal hyperplasia ( J:70670 )

• epidermis of affected mice (weanlings treated with doxycycline) exhibits hyperplasia